Abstract: This invention is based, in part, on our discovery of an essentially one-step, label-free system comprising a sensing unit having a redox current reporter and a nucleic acid sequence complementary to that of a target nucleic acid of interest or sufficiently complementary to that of the target nucleic acid or a sequence therein to specifically bind the target nucleic acid. The sensing unit is bound to an electroconductive substrate (e.g., a carbon- or metal-containing microelectrode (e.g., a gold microelectrode)), and the system includes a signal amplification mechanism that does not rely upon a redox enzyme and thereby overcomes a fundamental limitation of microelectrode DNA sensors that fail to generate detectable current in the presence of only small amounts of a target nucleic acid.
Type:
Grant
Filed:
July 6, 2016
Date of Patent:
October 26, 2021
Assignees:
GEORGIA STATE RESEARCH FOUNDATION, INC., THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS
Abstract: This disclosure relates to conjugates for targeting bacteria and related uses. In certain embodiments, the disclosure relates to methods of transferring a molecule of interest into bacteria comprising mixing bacteria with a non-naturally occurring conjugate under conditions such that the conjugate is transported across the bacterial cell wall. Typically, the conjugate comprises an oligosaccharide and a molecule of interest. In certain embodiments, the molecule of interest may be a tracer or an antibiotic.
Type:
Application
Filed:
February 26, 2014
Publication date:
August 7, 2014
Applicants:
Emory University, Georgia State Research Foundation, Georgia Tech Research Corporation
Inventors:
Niren MURTHY, Eric Seth Gilbert, Xinghai Ning, Mark Goodman, Bryan Stubblefield
Abstract: The present invention provides methods for treating retroviral infection and methods of treating HIV infection. The methods of the present invention include administering compounds of the general Formula I: ##STR1## wherein L, R.sub.1, R.sub.2, R.sub.3, R.sub.4 are defined herein.
Type:
Grant
Filed:
February 28, 1997
Date of Patent:
August 10, 1999
Assignees:
The University of North Carolina at Chapel Hill, Auburn University, Georgia State Research Foundation, Inc.
Inventors:
Christine C. Dykstra, David Boykin, Richard R. Tidwell
Abstract: The entire rubella virus genomic RNA has been sequenced. An infectious cDNA clone has been constructed. Mutants of this clone that are rendered non-pathogenic are used as vaccines to vaccinate humans, including pregnant or older women, with decreased risk of causing fetal infection, autoimmune disease or neurological symptoms.
Type:
Grant
Filed:
July 19, 1993
Date of Patent:
August 8, 1995
Assignee:
Georgia State Research Foundation, Inc.
Inventors:
Teryl K. Frey, Geraldina Dominguez, Chin-Yen Wang